Cancer/testis antigens expression during cultivation of melanoma and soft tissue sarcoma cells
| Autor: | A. V. Misyurin, Anna Danilova, Aleksei Viktorovich Novik, Irina Baldueva, Dmitry Viktorovich Girdyuk, Tatiana Nekhaeva, Natalia Avdonkina, Natalia Viktorovna Emelyanova, Nino Pipia, V. A. Misyurin |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Dendritic cell vaccine medicine.medical_treatment lcsh:RC254-282 03 medical and health sciences 0302 clinical medicine medicine Tumor cells lines cardiovascular diseases Melanoma PRAME business.industry Soft tissue sarcoma Research Cancer Immunotherapy lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens medicine.disease 030104 developmental biology Oncology Cell culture 030220 oncology & carcinogenesis Cancer research Soft and bone tissues sarcoma Cancer/testis antigens Sarcoma business |
| Zdroj: | Clinical Sarcoma Research Clinical Sarcoma Research, Vol 10, Iss 1, Pp 1-14 (2020) |
| ISSN: | 2045-3329 |
| Popis: | Background Autologous dendritic cells (DC) loaded with tumor-associated antigens (TAAs) are a promising approach for anticancer immunotherapy. Polyantigen lysates appear to be an excellent source of TAAs for loading onto the patient’s dendritic cells. Cancer/testis antigens (CTA) are expressed by a wide range of tumors, but are minimally expressed on normal tissues, and could serve as a universal target for immunotherapy. However, CTA expression levels can vary significantly in patients with the same tumor type. We proposed that patients who do not respond to DC-based therapy may have distinct features of the CTA expression profile on tumor cells. Patients and methods We compared the gene expression of the principal families CTA in 22 melanoma and 27 soft tissue and bone sarcomas cell lines (STBS), received from patients and used for DC vaccine preparation. Results The majority (47 of 49, 95.9%) cell lines showed CTA gene activity. The incidence of gene expression of GAGE, NYESO1, MAGEA1, PRAME’s was significantly different (adj. p SCP1 gene was detected neither in melanoma cells nor in the STBS cells. Clustering by the gene expression profile revealed four different expression patterns. We found three main patterns types: hyperexpression of multiple CTA, hyperexpression of one CTA with almost no expression of others, and no expression of CTA. All clusters types exist in melanoma and sarcoma cell lines. We observed dependence of killing efficacy from the PRAME (rho = 0.940, adj. p Conclusion Our results demonstrate that one can use lysates from allogeneic melanoma cell lines as a source of CTA for DC load during the production of anticancer vaccines for the STBS treatment. Patterns of CTA expression should be evaluated as biomarkers of response in prospective clinical trials. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink